A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)
Bradley J. Monk,Christine Parkinson,Myong Cheol Lim,David M. O'Malley,Ana Oaknin,Michelle K. Wilson,Robert L. Coleman,Domenica Lorusso,Paul Bessette,Sharad Ghamande,Athina Christopoulou,Diane Provencher,Emily Prendergast,Fuat Demirkiran,Olga Mikheeva,Oladapo Yeku,Anita Chudecka-Glaz,Michael Schenker,Ramey D. Littell,Tamar Safra,Hung-Hsueh Chou,Mark A. Morgan,Vít Drochýtek,Joyce N. Barlin,Toon Van Gorp,Fred Ueland,Gabriel Lindahl,Charles Anderson,Dearbhaile C. Collins,Kathleen Moore,Frederik Marme,Shannon N. Westin,Iain A. McNeish,Danny Shih,Kevin K. Lin,Sandra Goble,Stephanie Hume,Keiichi Fujiwara,Rebecca S. Kristeleit
DOI: https://doi.org/10.1200/JCO.22.01003
IF: 45.3
2022-06-08
Journal of Clinical Oncology
Abstract:PURPOSE ATHENA (ClinicalTrials.gov identifier: NCT03522246) was designed to evaluate rucaparib first-line maintenance treatment in a broad patient population, including those without BRCA1 or BRCA2 (BRCA) mutations or other evidence of homologous recombination deficiency (HRD), or high-risk clinical characteristics such as residual disease. We report the results from the ATHENA–MONO comparison of rucaparib versus placebo. METHODS Patients with stage III-IV high-grade ovarian cancer undergoing surgical cytoreduction (R0/complete resection permitted) and responding to first-line platinum-doublet chemotherapy were randomly assigned 4:1 to oral rucaparib 600 mg twice a day or placebo. Stratification factors were HRD test status, residual disease after chemotherapy, and timing of surgery. The primary end point of investigator-assessed progression-free survival was assessed in a step-down procedure, first in the HRD population (BRCA-mutant or BRCA wild-type/loss of heterozygosity high tumor), and then in the intent-to-treat population. RESULTS As of March 23, 2022 (data cutoff), 427 and 111 patients were randomly assigned to rucaparib or placebo, respectively (HRD population: 185 v 49). Median progression-free survival (95% CI) was 28.7 months (23.0 to not reached) with rucaparib versus 11.3 months (9.1 to 22.1) with placebo in the HRD population (log-rank P = .0004; hazard ratio [HR], 0.47; 95% CI, 0.31 to 0.72); 20.2 months (15.2 to 24.7) versus 9.2 months (8.3 to 12.2) in the intent-to-treat population (log-rank P < .0001; HR, 0.52; 95% CI, 0.40 to 0.68); and 12.1 months (11.1 to 17.7) versus 9.1 months (4.0 to 12.2) in the HRD-negative population (HR, 0.65; 95% CI, 0.45 to 0.95). The most common grade ≥ 3 treatment-emergent adverse events were anemia (rucaparib, 28.7% v placebo, 0%) and neutropenia (14.6% v 0.9%). CONCLUSION Rucaparib monotherapy is effective as first-line maintenance, conferring significant benefit versus placebo in patients with advanced ovarian cancer with and without HRD.
oncology